In a preclinical model, it has managed to reduce the amount of toxic proteins in the brain, whose aggregation is the main reason for neuronal death in Alzheimer’s”Eliminating toxic proteins from the brain is the objective of most current therapies against Alzheimer’s”, details the researcherThe novelty of this research is that it proposes to reduce toxins from the blood, where they are alsoA new study carried out by the scientist from the University of Malaga Inés Moreno, in collaboration with the University of Texas (United States), has identified a possible non-invasive therapy that could curb Alzheimer’s disease. Moreno has managed to reduce the amount of toxic proteins in the brain, whose aggregation is the main cause of neuronal death in Alzheimer’s, in a preclinical model, by up to 40-80 percent. These proteins are also found in the blood and, according to the UMA expert, are in balance with the brain: if it increases in the brain increases in blood and vice versa. Based on these results, Moreno proposes the elimination of toxic aggregates as a therapeutic target against the disease. The work has been published in the scientific journal ‘Molecular Psychiatry’. “Eliminating toxic proteins from the brain is the goal of most current therapies against Alzheimer’s”, explains the researcher from the UMA ‘NeuroAD’ group. toxins from the blood The novelty of this research is that it proposes to reduce toxins from the blood, where they are also found. “We have found that, if we remove toxins from the blood, they would drain from the brain into the blood again in search of balance, improving the clinical signs and pathology of the disease,” says Moreno. The scientist affirms that, currently, the analysis of blood samples is already used, on some occasions, for the diagnosis of the disease as an alternative to neuroimaging. However, to date, it has never been used for the purpose demonstrated in this work. For this reason, this new use “opens the door to possible non-invasive therapeutic strategies that act at the circulatory level”. Thus, the results tested in animal models have shown that this treatment would improve memory and learning capacity, correcting cognitive errors, and may not only eliminate toxic proteins, but also modify other important factors in the development of the disease. The University of Texas, where Inés Moreno is an associate professor, will continue this study at the clinical level, seeking to determine the molecular mechanisms involved in this improvement of the disease and, also, if the treatment would work in patients undergoing, for example, dialysis for patients with dementia or even transfusions.